CHICAGO (MedPage Today) -- The recently approved HIV drug rilpivirine (Edurant) is easier to take for the first three months of therapy than the widely used efavirenz (Sustiva), a researcher said.
efavirenzICAAC: New Drug Easier to Take than HIV Standard (CME/CE)MedPage Today Infectious Disease Thu, 09/22/2011 - 09:00
CHICAGO (MedPage Today) -- The recently approved HIV drug rilpivirine (Edurant) is easier to take for the first three months of therapy than the widely used efavirenz (Sustiva), a researcher said. New Antiretroviral Drug Effective as First HIV Treatment (CME/CE...MedPage Today Infectious Disease Mon, 08/03/2009 - 16:35
The new antiretroviral raltegravir (Isentress) is an effective first treatment for HIV and suppresses HIV replication far more rapidly than efavirenz,, with fewer adverse events according to a study funded by the manufacturer IAS: Raltegravir Sustains High-level Efficacy in HIV Trial (CME/...MedPage Today Infectious Disease Wed, 07/22/2009 - 11:14
CAPE TOWN (MedPage Today) -- The integrase inhibitor raltegravir (Isentress) appeared to be as effective with HIV patients as the standard treatment based on efavirenz (Sustiva), researchers reported here. Stepped Dosing Lessens Neuropsychiatric Effects of Efavirenz (CM...MedPage Today Infectious Disease Mon, 07/06/2009 - 15:00
LITTLE FALLS, N.J. (MedPage Today) -- A stepwise dosing schedule eases the neuropsychiatric side effects of the HIV drug efavirenz (Sustiva), a randomized trial showed. |